Our group is interested in a broad array of clinical and translational investigations spanning the evaluation of basic pathophysiology in patients undergoing cardiac procedures, development and evaluation of new therapeutic strategies, and improving patient selection and outcomes following interventional procedures. We are comprised of a core group of faculty and dedicated research nurses as well as fellows, residents, and students. Projects range from investigator-initiated single-center observational studies to industry-sponsored multicenter phase 3 randomized controlled trials. We have established a database of all patients who have undergone TAVR at Johns Hopkins, which is providing the basis for several retrospective analyses and will serve as the foundation for future studies of TAVR. We are also engaged in collaborative projects with other groups from the Department of Medicine and other Departments including Cardiac Surgery, Anesthesiology, Radiology, Psychiatry, and Biomedical Engineering. Members of our group are actively involved with the Johns Hopkins Center for Bioengineering Innovation and Design (CBID) in the development of novel minimally-invasive cardiovascular devices.

Research in the Hanan Aboumatar Lab focuses on advancing patient-centered outcomes through improved patient and family involvement. We also focus on multilevel methods to increase the patient-centered focus of care delivery. Recent research examined the impact of a quality-improvement intervention on patient involvement in primary care and treatment with respect and dignity in intensive care.

Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesity and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans.

The Timothy Niessen Lab studies patient outcomes in the ICU. We are particularly interested in the effects of sleep quality, delirium transitions and sedation on the improvement of intensive care patients. Our investigators also focus on the practices of internal medicine interns, studying the variability of hand washing hygiene, etiquette-based communication and time spent in direct and indirect patient care. We have also studied the onset of myelopathy as a result of B12 deficiency from long-term colchicine treatment and recreational nitrous oxide use.

We are devoted to developing and deploying cutting edge technologies that can be used to define human immune responses. Much of our work leverages ‘next generation’ DNA sequencing, which enables massively parallel molecular measurements. Examples of our technologies include: - bacteriophage display of synthetic peptidome libraries for comprehensive, quantitative profiling of antibodies; - display of ORFeome libraries for antigen discovery, protein-protein interaction studies, and drug target identification; - ultrasensitive, multiplex RNA quantification techniques to monitor gene expression and detect microbes; - pooled genetic screening to elucidate immune cell function and identify new therapeutic targets. The Larman Laboratory uses these and other approaches to identify opportunities for monitoring and manipulating immune responses.

Research conducted in the Todd Dorman Lab examines the use of informatics in intensive care settings as it relates to remote patient monitoring, safety and management strategies. Specific areas of interest include the surgical stress response; aminoglycoside antibiotics; fungal infections; renal failure; pharmacokinetic models of drug administration; and ICU triage and its impact on disaster preparedness.

The Tom Woolf Lab studies the quarter of the genome devoted to membrane proteins. This rapidly growing branch of bioinformatics, which includes computational biophysics, represents the main research direction of our group. We aim to provide insight into critical issues for membrane systems. In pursuit of these goals, we use extensive computer calculations to build an understanding of the relations between microscopic motions and the world of experimental measurements. Our calculations use our own Beowulf computer cluster as well as national supercomputer centers. An especially strong focus has been on the computed motions of proteins and all-atom models of the lipid bilayers that mediate their influence. To compute these motions, we use the molecular dynamics program CHARMM. We hope to use our understanding of the molecular motions for the prediction of membrane protein structures using new computational methods.

Researchers in the Robert Greenberg Lab examine anesthesiology and critical care-related topics that include critical airway management, non-invasive fetal monitoring, neural blockade monitoring, pediatric acute pain management, cuffed oropharyngeal airway (COPA), pain informatics, and pediatric pain education and innovation.

Work in the Robert H. Brown Lab explores several topics within pulmonary physiology, with a long-term goal of understanding the structural changes in the lungs that lead to the pathophysiology of lung disease. Our core studies examine the structure-function relationship of pulmonary airways and vessels as well as their role in chronic obstructive pulmonary disease (COPD) and reactive airway disease. Recent research has involved studying the mechanisms and treatment of COPD progression, new methods for treating asthma, and lung inflation and airway hyperresponsiveness. We are also exploring the impact of HIV infection on the etiology of lung disease and the pathophysiologic consequences of lung distention.

Dr. Yegnasubramanian directs a Laboratory of Cancer Molecular Genetics and Epigenetics at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), and is also the Director of the SKCCC Next Generation Sequencing Center. Our lab research is focused on understanding the complex interplay between genetic and epigenetic alterations in carcinogenesis and disease progression, and to exploit this understanding in developing novel biomarkers for diagnosis and risk stratification as well as in identifying targets for therapeutic intervention.